Endoscopic Retrograde Cholangiopancreatography Market/ERCP Market

Endoscopic Retrograde Cholangiopancreatography Market/ERCP Market by Product (Upper GI endoscopes, Stent, Balloons, Catheters, Baskets), Procedure (Biliary Sphincterotomy & Stenting, Pancreatic Sphincterotomy), End User (Hospitals) (2022 - 2026)

Report Code: MD 8059 Mar, 2022, by marketsandmarkets.com

[237 Pages Report] The global endoscopic retrograde cholangiopancreatography market is projected to reach USD 2.0 billion by 2026 from USD 1.3 billion in 2021, at a CAGR of 9.6% during the forecast period. The drivers of the market include the rising incidence of cancer, increasing investments by governments and healthcare organizations to improve endoscopy research, growing focus on investments by hospitals for advanced endoscopy instruments, and the increasing preference for minimally invasive surgeries.

Endoscopic Retrograde Cholangiopancreatography/ERCP Market

To know about the assumptions considered for the study, Request for Free Sample Report

Covid-19 Impact on the Endoscopic retrograde cholangiopancreatography Market

The COVID-19 pandemic has resulted in a global crisis. Surgeons and patients visiting hospitals for various treatments are at increased risk of getting infected by COVID-19. Most of the gastrointestinal procedures were suspended, leading to a decrease in device-based treatments such as ERCP. Around 40–50% of endoscopy procedures were canceled in major hospitals across Germany. According to a research study, the COVID-19 pandemic significantly reduced ERCP procedures. The success rate was also lowered due to restrictions on endoscopic services in the UK and worldwide. This negatively impacted the ERCP market. Moreover, endoscopy is considered an aerosol-generating procedure, which imposes the risk of transmission to health care professionals. Nevertheless, the providers use PPE kits and further precaution measures to continue endoscopy procedures.

The sales of disposable endoscopes have risen in contrast to autoclavable endoscopes as many hospitals and clinics lack the resources and manpower to adhere to and implement the stringent COVID-19 guidelines put forth by the European Society for Gastrointestinal Endoscopy (ESGE) and the German Respiratory Society (Deutsche Gesellschaft fόr Pneumologie und Beatmungsmedizin or DGP). The use of negative pressure suites and personal protective kits and spatial separation of wards are recommended to avoid the risk of infection. Additionally, a research study revealed that the use of Enhanced Personal Protective Equipment (EPPE) had no negative effects on ERCP performance in this patient group. This meant that ERCP could be effectively performed under EPPE. As a result, the overall cost of endoscopic treatment has increased. These factors have restrained the growth of the ERCP market. However, with the rollout of vaccines worldwide, the market will likely recover in the coming years.

Endoscopic retrograde cholangiopancreatography Market Dynamics

Driver: Rising incidence of cancer

Nowadays, the global incidence of cancer is increasing. According to the WHO, cancer is the second-leading cause of death globally and was responsible for 9.6 million deaths in 2018. According to the American Cancer Society’s estimates, about 41,260 new cases of liver cancer and intrahepatic bile duct cancer will be diagnosed in 2022 in the US. Liver cancer incidence rates have more than tripled since 1980, while the death rates have more than doubled during this time. In 2021, around 60,430 new pancreatic cases were diagnosed in the US. In the UK (2016-2018), around 10,500 new pancreatic cancer cases and 6,200 liver cancer cases every year. Globally, 458,918 new cases of pancreatic cancer were reported in 2018, and 355,317 new cases are estimated to occur until 2040 (GLOBOCAN 2018 estimates).
Since ERCP is often used as a diagnostic tool in hepatic, bile duct, and pancreatic cancers, the rising incidence of these cancers is directly related to the impact on the ERCP market

Restraint: High costs of endoscopic retrograde cholangiopancreatography devices

One of the most pertinent restraining factors for the market is the high costs of ERCP equipment and procedures. The average selling price of a duodenoscope is around USD 31,500 (Non- HD) to USD 37,000 (HD). This high price, combined with the long procedure time, makes this unfavorable. Additionally, an interview conducted with an expert in the ERCP market cost can be one of the leading reasons for the procedure not being easily accessible and affordable to many small-scale end users, which cater to a large population, especially in developing countries.

Opportunity: The growing healthcare sector in emerging economies

Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies globally. According to World Economic Forum, the emerging economies accounted for around one-third of the global healthcare expenditure in 2021. More than half of the world’s population resides in India and China, owing to which these countries are home to the highest number of patients.

The increasing burden of cancer, rapid improvements in healthcare infrastructure, the rapid growth of medical tourism, and the presence of flexible regulation in these countries encourage players in the endoscopy equipment market to expand their presence in emerging countries.

Several endoscopy equipment manufacturers are currently setting up their facilities in the Asia Pacific, the Middle East, and Latin America. Key players such as KARL STORZ have already set up their manufacturing and R&D facilities in these countries. In addition, market saturation in developed regions, such as North America and Europe, will compel manufacturers to focus on emerging markets in the coming years.

These factors are expected to offer significant growth opportunities for the ERCP market.

By product type segment, the largest share of the market was occupied by the endotherapy devices segment during the forecast period.

This is due to driving factors such as the growth of minimally invasive surgeries and the increasing prevalence of gastrointestinal conditions.

Under endotherapy devices, sphincterotomes accounted for the largest share during the forecast period.

The increasing incidence of pancreatic duct and bile duct stones and the increase in geriatric population (and therefore, an increase in biliary disorders).

Endoscopic Retrograde Cholangiopancreatography/ERCP Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Asia-Pacific and Latin America are the fastest-growing markets for endoscopic retrograde cholangiopancreatography market during the forecast period.

Governments in several Latin American countries focus on improving their respective healthcare systems, and the healthcare sector in Brazil has undergone significant changes, making the country one of the world's most promising and attractive markets. Along with this, Japan’s well-developed healthcare system with universal health insurance coverage, and the focus of countries such as China and India on healthcare infrastructure improvements to serve large populations of patients with critical illnesses, including cancer, and tumors are driving the market in these regions forward at a rapid pace.

Key Market Players

The major players in the global endoscopic retrograde cholangiopancreatography market include Olympus Corporation (Japan), CONMED Corporation (US), Fujifilm Holdings Corporation (Japan), HOYA Corporation (Japan), KARL STORZ SE & Co. KG (Germany), Ambu A/S (Denmark), Boston Scientific Corporation (US), Johnson & Johnson (US), Medtronic, PLC (Ireland), Cook Medical (US), and B. Braun Melsungen AG (Germany).

Other players in the market include Hobbs Medical, Inc. (US), STERIS PLC (US), Merit Medical Systems, Inc. (US), TeleMed Systems, Inc. (US), Changzhou Health Microport Medical Device Co., LTD. (China), Medi-Globe GmbH (Germany), Taewoong Medical Co., Ltd. (South Korea), Huger Medical Instrument Co., Ltd. (China), IntroMedic Co., Ltd. (Republic of Korea), SonoScape Medical Corporation (China), Shanghai AOHUA Photoelectricity Endoscope Co., Ltd. (China), Ottomed (India), Kimberly-Clark Corporation (US), and Shaili Endoscopy (India)

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Value (USD)

Segments covered

Product, procedure, end-user, and region

Geographies covered

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

Companies covered

  • Olympus Corporation (Japan)
  • CONMED Corporation (US)
  • Fujifilm Holdings Corporation (Japan)
  • HOYA Corporation (Japan)
  • KARL STORZ SE & Co. KG (Germany)
  • Ambu A/S (Denmark)
  • Boston Scientific Corporation (US)
  • Johnson & Johnson (US)
  • Medtronic, PLC (Ireland)
  • Cook Medical (US)
  • B. Braun Melsungen AG (Germany)
  • Hobbs Medical, Inc. (US)
  • STERIS PLC (US)
  • Merit Medical Systems, Inc. (US)
  • TeleMed Systems, Inc. (US)
  • Changzhou Health Microport Medical Device Co., LTD. (China)
  • Medi-Globe GmbH (Germany)
  • Taewoong Medical Co., Ltd. (South Korea)
  • Huger Medical Instrument Co., Ltd. (China)
  • IntroMedic Co., Ltd. (Republic of Korea)
  • SonoScape Medical Corporation (China)
  • Shanghai AOHUA Photoelectricity Endoscope Co., Ltd. (China)
  • Ottomed (India)
  • Kimberly-Clark Corporation (US)
  • Shaili Endoscopy (India)

The research report categorizes the Endoscopic retrograde cholangiopancreatography market into the following segments and subsegments:

Product

  • Endoscopes
  • Endotherapy Devices
    • Sphincterotomes
    • Lithotripter
    • Stents
    • Cannulas
    • Forceps
    • Snares
    • Catheters
    • Guiding Wires
    • Balloons
    • Baskets
  • Visualization Systems
  • Energy Devices
  • Others

Procedure

  • Biliary Sphincterotomy
  • Biliary Stenting
  • Biliary Dialtation
  • Pancreatic Sphincterotomy
  • Pancreatic Duct Stenting
  • Pancreatic Duct Dilatation

End User

  • Hospitals
  • Ambulatory Surgery Centres & Clinics
  • Other End Users

Region

  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
  • Middle East
  • Africa

Recent Developments

  • In January 2022, Cook Medical (US) launched an endoscopic clipping device, namely Instinct Plus, which is compatible through a duodenoscope, has applications for defect closure, anchoring procedures and prophylactic clipping in the gastrointestinal (GI) tract.
  • In May 2021, STERIS PLC (US) acquired Cantel Medical (US) which enabled STERIS Healthcare to expand its product portfolio and cater to customers worldwide. 
  • In March 2021, Fujifilm Holdings Corporation (Japan) acquired Hitachi, Ltd.’s Diagnostic Imaging-related Business (Japan), adding to the former’s stronghold in the healthcare business.
  • In October 2020, Olympus Corporation (Japan) launched two endotherapy devices, StoneMasterV and VorticCatchV, to increase the efficiency in bile duct stone management and retrieval for ERCP announced a partnership with Holberg to develop and distribute the Autoscore algorithm.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 29)
    1.1 STUDY OBJECTIVES
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
                    FIGURE 1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
           1.3.2 YEARS CONSIDERED
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY (Page No. - 34)
    2.1 RESEARCH DATA
           FIGURE 2 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 3 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS (ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET)
                               FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
    2.2 MARKET SIZE ESTIMATION
           FIGURE 6 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 7 REVENUE SHARE ANALYSIS ILLUSTRATION: OLYMPUS CORPORATION
           FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2020)
           FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES FOR THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)
           FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           FIGURE 11 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 12 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 STUDY ASSUMPTIONS
    2.6 LIMITATIONS
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT
    2.8 ASSESSMENT OF IMPACT OF COVID-19 ON ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

3 EXECUTIVE SUMMARY (Page No. - 48)
    FIGURE 13 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2021 VS. 2026 (USD MILLION)
    FIGURE 15 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 16 GEOGRAPHICAL SNAPSHOT OF THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET

4 PREMIUM INSIGHTS (Page No. - 51)
    4.1 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET OVERVIEW
           FIGURE 17 INCREASING INCIDENCE OF CANCER AND THE GROWING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES ARE THE KEY FACTORS DRIVING MARKET GROWTH
    4.2 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES
           FIGURE 18 CHINA TO WITNESS THE HIGHEST GROWTH IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET DURING THE FORECAST PERIOD
    4.3 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT AND COUNTRY (2020)
           FIGURE 19 THE ENDOSCOPES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE ERCP MARKET IN NORTH AMERICA FOR 2020
    4.4 REGIONAL MIX: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET (2021–2026)
           FIGURE 20 THE ASIA PACIFIC AND LATIN AMERICA REGIONS ARE EXPECTED TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD (2021–2026)
    4.5 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 21 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 55)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 22 MARKET DYNAMICS: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
           5.2.1 MARKET DRIVERS
                    5.2.1.1 Rising incidence of cancer
                               FIGURE 23 GLOBAL AGE-STANDARDIZED INCIDENCE RATES OF PANCREATIC CANCER, 2020
                    5.2.1.2 Increasing investments, funds, and grants by governments and healthcare organizations to improve endoscopy research
                               TABLE 1 MAJOR DEVELOPMENTS
                    5.2.1.3 Growing focus on investments by hospitals for advanced endoscopy instruments
                               TABLE 2 SOME EXAMPLES OF INVESTMENTS BY HOSPITALS FOR ENDOSCOPY INSTRUMENTS
                    5.2.1.4 Increasing preference for minimally invasive surgeries
                               FIGURE 24 ENDOSCOPIC GLOBAL MINIMALLY INVASIVE MARKET SIZE (2019-2030)
           5.2.2 MARKET RESTRAINTS
                    5.2.2.1 High costs of endoscopic retrograde cholangiopancreatography devices
                    5.2.2.2 Development of other procedures like EUS and MRCP
                    5.2.2.3 Shortage of trained physicians and endoscopists
           5.2.3 MARKET OPPORTUNITIES
                    5.2.3.1 The growing healthcare sector in emerging economies
                    5.2.3.2 Increasing adoption of single-use endoscopy instruments
           5.2.4 MARKET CHALLENGES
                    5.2.4.1 Product recalls witnessed by major market players
                               TABLE 3 LIST OF PRODUCT RECALLS
                    5.2.4.2 Side-effects and infections (like post-ERCP pancreatitis) caused by duodenoscopy products

6 INDUSTRY INSIGHTS (Page No. - 63)
    6.1 INTRODUCTION
    6.2 TECHNOLOGY TRENDS
           6.2.1 ARTIFICIAL INTELLIGENCE IN GI ENDOSCOPY
                    TABLE 4 AI SYSTEMS AND OTHER RELATED FUNCTIONS
           6.2.2 SINGLE-USE ENDOSCOPES
                    TABLE 5 ADVANTAGES OF DISPOSABLE OR SINGLE-USE ENDOSCOPES OVER REUSABLE ENDOSCOPES
           6.2.3 ROBOT-ASSISTED ENDOSCOPES
                    TABLE 6 ROBOT-ASSISTED ENDOSCOPY PRODUCTS
    6.3 INDUSTRY TRENDS
           6.3.1 FAVOURABLE REIMBURSEMENT SCENARIO FOR SINGLE-USE DEVICES
    6.4 PRICING ANALYSIS
           TABLE 7 AVERAGE SELLING PRICE OF FLEXIBLE HD AND NON-HD DUODENOSCOPE (USD)
           TABLE 8 US: AVERAGE COST OF ERCP PROCEDURES, 2020 (USD)
    6.5 VALUE CHAIN ANALYSIS
           FIGURE 25 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE
    6.6 ECOSYSTEM MAPPING
           FIGURE 26 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: ECOSYSTEM ANALYSIS
    6.7 SUPPLY CHAIN ANALYSIS
           FIGURE 27 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: STAKEHOLDERS IN SUPPLY CHAIN
    6.8 PORTER’S FIVE FORCES ANALYSIS
           TABLE 9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: PORTER’S FIVE FORCES ANALYSIS
           6.8.1 THREAT OF NEW ENTRANTS
                    6.8.1.1 High capital requirement
                    6.8.1.2 High preference for products from well-established brands
           6.8.2 THREAT OF SUBSTITUTES
                    6.8.2.1 Substitute therapies for ERCP procedures
           6.8.3 BARGAINING POWER OF SUPPLIERS
                    6.8.3.1 Presence of several raw material suppliers
                    6.8.3.2 Supplier switching costs
           6.8.4 BARGAINING POWER OF BUYERS
                    6.8.4.1 Few companies offer premium products at the global level
           6.8.5 INTENSITY OF COMPETITIVE RIVALRY
                    6.8.5.1 Increasing demand for high-quality and innovative products
                    6.8.5.2 Lucrative growth potential in emerging markets
    6.9 REGULATORY ANALYSIS
    6.10 PATENT ANALYSIS
           6.10.1 PATENT PUBLICATION TRENDS FOR ERCP
                     FIGURE 28 GLOBAL PATENT PUBLICATION TRENDS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, 2017–2021
           6.10.2 TOP APPLICANTS (COMPANIES) OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS
                     FIGURE 29 TOP COMPANIES THAT APPLIED FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021
           6.10.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
                     FIGURE 30 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY PATENTS, 2017–2021
    6.11 TRADE ANALYSIS
           TABLE 10 NUMBER OF EXPORTS AND IMPORTS RELATED TO ERCP EQUIPMENT
    6.12 IMPACT OF COVID-19 ON THE ENDOSCOPY EQUIPMENT MARKET

7 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT (Page No. - 78)
    7.1 INTRODUCTION
           TABLE 11 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    7.2 ENDOSCOPES
           7.2.1 THE RISING PREFERENCE FOR MINIMALLY INVASIVE SURGERIES IS EXPECTED TO DRIVE THE ENDOSCOPES MARKET
                    TABLE 12 ENDOSCOPES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 ENDOTHERAPY DEVICES
           7.3.1 THESE ARE MINIMALLY INVASIVE DEVICES USED TO TREAT OR DIAGNOSE GI CONDITIONS
                    TABLE 13 ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                    TABLE 14 ENDOTHERAPY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.2 SPHINCTEROTOME
                    7.3.2.1 The risk of bleeding post-sphincterotomy is 2%, with 0.1% mortality
                               TABLE 15 SPHINCTEROTOME MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.3 LITHOTRIPTER
                    7.3.3.1 Lithotripters are used to pulverize stones into smaller pieces so that they can pass out of a body naturally
                               TABLE 16 LITHOTRIPTER MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.4 STENTS
                    7.3.4.1 Metal stents have higher patency rates and are less expensive than plastic stents
                               TABLE 17 STENTS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.5 CANNULAS
                    7.3.5.1 The success rate of ERCP procedures is directly proportional to cannulation
                               TABLE 18 CANNULAS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.6 FORCEPS
                    7.3.6.1 The prevalence of cancer leads to significant demand for biopsy forceps for the collection of tissue samples
                               TABLE 19 FORCEPS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.7 SNARES
                    7.3.7.1 Snares are commonly used for cold or hot polypectomy
                               TABLE 20 SNARES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.8 CATHETERS
                    7.3.8.1 Catheters inject a contrast medium for the visualization of internal tissues
                               TABLE 21 CATHETERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.9 GUIDING WIRES
                    7.3.9.1 The most used guidewires in ERCP come in three different diameters: 0.018, 0.025, and 0.035 inches
                               TABLE 22 GUIDING WIRES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.10 BALLOONS
                    7.3.10.1 Balloon endoscopy involves balloons that inflate and deflate to pinch together the walls of the GI tract
                                TABLE 23 BALLOONS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.11 BASKETS
                    7.3.11.1 Baskets are commonly used instruments for the removal of bile duct stones in ERCP
                                TABLE 24 BASKETS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.4 VISUALIZATION SYSTEMS
           7.4.1 VISUALIZATIONS SYSTEMS HAVE APPLICATIONS ACROSS ALL ERCP PROCEDURES
                    TABLE 25 VISUALIZATION SYSTEMS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.5 ENERGY DEVICES
           7.5.1 ENERGY DEVICES CAN BE MONOPOLAR OR BIPOLAR
                    TABLE 26 ENERGY DEVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.6 OTHERS
           TABLE 27 ERCP ACCESSORIES AND DESCRIPTIONS
           TABLE 28 OTHERS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE (Page No. - 96)
    8.1 INTRODUCTION
           TABLE 29 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
    8.2 BILIARY SPHINCTEROTOMY
           8.2.1 INCREASING INCIDENCE RATES OF SOD TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 30 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 BILIARY DILATATION
           8.3.1 HIGH-CHOLESTEROL DIETS AND OBESITY ARE THE KEY CAUSES OF GALLSTONES, THUS DRIVING THE UPTAKE OF BILIARY DILATATION PROCEDURES
                    TABLE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)
    8.4 BILIARY STENTING
           8.4.1 THE RISING PREVALENCE OF GALLBLADDER DISEASES IN THE GROWING GERIATRIC POPULATION IS EXPECTED TO PROPEL THE DEMAND FOR BILIARY STENTS
                    TABLE 32 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR BILIARY STENTING, BY COUNTRY, 2019–2026 (USD MILLION)
    8.5 PANCREATIC SPHINCTEROTOMY
           8.5.1 THE RISING INCIDENCE OF PANCREATIC CANCER IS EXPECTED TO DRIVE THE DEMAND FOR THIS PROCEDURE
                    TABLE 33 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC SPHINCTEROTOMY, BY COUNTRY, 2019–2026 (USD MILLION)
    8.6 PANCREATIC DUCT DILATATION
           8.6.1 BALLOON DILATION ALONG WITH ENDOSCOPIC SPHINCTEROTOMY IS THE PREFERRED PROCEDURE FOR STONE REMOVAL
                    TABLE 34 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT DILATATION, BY COUNTRY, 2019–2026 (USD MILLION)
    8.7 PANCREATIC DUCT STENTING
           8.7.1 PANCREATIC DUCT STENTING IS THE TREATMENT OF CHOICE FOR CHRONIC PANCREATIC DISORDERS
                    TABLE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR PANCREATIC DUCT STENTING, BY COUNTRY, 2019–2026 (USD MILLION)

9 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER (Page No. - 104)
    9.1 INTRODUCTION
           TABLE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
    9.2 HOSPITALS
           9.2.1 INCREASING INVESTMENTS BY GOVERNMENT ORGANISATIONS BOOST THE ADOPTION OF ERCP BY THIS END-USER SEGMENT
                    TABLE 37 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 AMBULATORY SURGERY CENTERS/CLINICS
           9.3.1 AMBULATORY SURGERY CENTERS PROVIDE OUTPATIENT ECRP PROCEDURES THROUGH EFFICIENT OPERATIONS
                    TABLE 38 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR AMBULATORY SURGERY CENTERS/CLINICS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 OTHER END USERS
           TABLE 39 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)

10 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION (Page No. - 109)
     10.1 INTRODUCTION
             FIGURE 31 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
             TABLE 40 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY REGION, 2019–2026 (USD MILLION)
     10.2 NORTH AMERICA
             FIGURE 32 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT
             TABLE 41 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 42 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 43 NORTH AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 44 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
             TABLE 45 NORTH AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.1 US
                        10.2.1.1 The large market in the US is mainly driven by high healthcare spending in the country and the increasing incidence of cancer
                                     TABLE 46 MEDICARE NATIONAL AVERAGE COVERAGE FOR OUTPATIENT PROCEDURES, 2020
                                     TABLE 47 LIST OF DEVICES THAT RECEIVED FDA APPROVALS BETWEEN 2018 AND 2021
                                     TABLE 48 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 49 US: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 50 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 51 US: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.2.2 CANADA
                        10.2.2.1 High costs of endoscopic retrograde cholangiopancreatography to restrain the market growth in Canada
                                     TABLE 52 INCIDENCE ESTIMATES BY CANCER TYPE (CANADA)
                                     TABLE 53 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 54 CANADA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 55 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 56 CANADA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.3 EUROPE
             TABLE 57 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 58 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 59 EUROPE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 60 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
             TABLE 61 EUROPE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.1 GERMANY
                        10.3.1.1 Germany’s rising geriatric population is one of the key drivers for the ERCP market
                                     TABLE 62 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 63 GERMANY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 64 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 65 GERMANY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.2 UK
                        10.3.2.1 Investments by hospitals to purchase new & advanced ERCP equipment is expected to propel market growth in the UK
                                     TABLE 66 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 67 UK: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 68 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 69 UK: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.3 FRANCE
                        10.3.3.1 High healthcare expenditure is expected to support the growth of the ERCP market in France
                                     TABLE 70 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 71 FRANCE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 72 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 73 FRANCE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.4 SPAIN
                        10.3.4.1 Increasing prevalence of cardiovascular diseases in Spain to stimulate the market growth for endoscopes
                                     TABLE 74 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 75 SPAIN: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 76 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 77 SPAIN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Rising government initiatives for the adoption of advanced medical equipment to drive the market growth for ERCP equipment & procedures in Italy
                                     TABLE 78 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 79 ITALY: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 80 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 81 ITALY: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.3.6 REST OF EUROPE (ROE)
                        TABLE 82 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 83 ROE: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 84 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                        TABLE 85 ROE: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.4 ASIA PACIFIC
             FIGURE 33 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET SNAPSHOT
             TABLE 86 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 87 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 88 ASIA PACIFIC: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
             TABLE 89 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
             TABLE 90 ASIA PACIFIC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.1 JAPAN
                        10.4.1.1 Supportive medical device reimbursement policies to drive the market growth for ERCP in Japan
                                     TABLE 91 JAPAN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 92 JAPAN: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 93 JAPAN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 94 JAPAN: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 Large patient population and the strong need for healthcare infrastructure improvements to drive the market growth in China
                                     TABLE 95 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 96 CHINA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 97 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 98 CHINA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.3 INDIA
                        10.4.3.1 Favorable government initiatives for improvements in healthcare infrastructure to support the market growth for ERCP in India
                                     TABLE 99 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 100 INDIA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 101 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 102 INDIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.4 AUSTRALIA
                        10.4.4.1 The high number of cancer rates in Australia is expected to drive the demand for endoscopy instruments
                                     TABLE 103 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 104 AUSTRALIA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 105 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 106 AUSTRALIA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC (ROAPAC)
                        TABLE 107 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 108 ROAPAC: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 109 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                        TABLE 110 ROAPAC: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.5 LATIN AMERICA
             10.5.1 THE GOVERNMENTS IN MANY LATIN AMERICAN COUNTRIES ARE FOCUSED ON IMPROVING HEALTHCARE INFRASTRUCTURE, AND IN TURN, THE ADOPTION OF ERCP IS EXPECTED TO RISE
                        TABLE 111 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 112 LATIN AMERICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                        TABLE 113 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                        TABLE 114 LATIN AMERICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.5.2 MIDDLE EAST
                        10.5.2.1 Healthcare infrastructural advancements are expected to create the requirement for advanced hospital equipment such as ERCP in the region
                                     TABLE 115 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 116 MIDDLE EAST: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 117 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 118 MIDDLE EAST: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)
             10.5.3 AFRICA
                        10.5.3.1 High prevalence of target diseases and initiatives to strengthen endoscopic services in healthcare organizations to propel market growth
                                     TABLE 119 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 120 AFRICA: ENDOTHERAPY DEVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
                                     TABLE 121 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY PROCEDURE, 2019–2026 (USD MILLION)
                                     TABLE 122 AFRICA: ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET, BY END USER, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE (Page No. - 158)
     11.1 OVERVIEW
     11.2 KEY PLAYER STRATEGIES/RIGHT-TO-WIN
             11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
             FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
     11.4 COMPETITIVE BENCHMARKING
             TABLE 123 FOOTPRINT OF COMPANIES IN ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET
             TABLE 124 PRODUCT AND SERVICE: COMPANY FOOTPRINT (25 COMPANIES)
             TABLE 125 END USER: COMPANY FOOTPRINT (25 COMPANIES)
             TABLE 126 REGION: COMPANY FOOTPRINT (26 COMPANIES)
     11.5 COMPETITIVE LEADERSHIP MAPPING
             11.5.1 STAR
             11.5.2 EMERGING LEADER
             11.5.3 PERVASIVE PLAYER
             11.5.4 PARTICIPANT
                        FIGURE 35 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
     11.6 COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES
             11.6.1 PROGRESSIVE COMPANY
             11.6.2 DYNAMIC COMPANY
             11.6.3 STARTING BLOCK
             11.6.4 RESPONSIVE COMPANY
                        FIGURE 36 ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR OTHER COMPANIES (2020)
     11.7 MARKET RANKING ANALYSIS
             FIGURE 37 ERCP MARKET RANKING ANALYSIS, BY PLAYER, 2020
             FIGURE 38 ENDOTHERAPY DEVICES MARKET RANKING ANALYSIS, BY PLAYER, 2020
     11.8 COMPETITIVE SCENARIO
             TABLE 127 PRODUCT LAUNCHES & APPROVALS, 2019–2021
             TABLE 128 DEALS, 2019–2021

12 COMPANY PROFILES (Page No. - 173)
(Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made)* 
     12.1 KEY PLAYERS
             12.1.1 OLYMPUS CORPORATION
                        TABLE 129 OLYMPUS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 39 COMPANY SNAPSHOT: OLYMPUS CORPORATION (2020)
             12.1.2 CONMED CORPORATION
                        TABLE 130 CONMED CORPORATION: BUSINESS OVERVIEW
                        FIGURE 40 COMPANY SNAPSHOT: CONMED CORPORATION (2020)
             12.1.3 AMBU A/S
                        TABLE 131 AMBU A/S: BUSINESS OVERVIEW
                        FIGURE 41 COMPANY SNAPSHOT: AMBU A/S (2020)
             12.1.4 BOSTON SCIENTIFIC CORPORATION
                        TABLE 132 BOSTON SCIENTIFIC CORPORATION: BUSINESS OVERVIEW
                        FIGURE 42 COMPANY SNAPSHOT: BOSTON SCIENTIFIC CORPORATION (2020)
             12.1.5 JOHNSON & JOHNSON
                        TABLE 133 JOHNSON & JOHNSON: BUSINESS OVERVIEW
                        FIGURE 43 COMPANY SNAPSHOT: JOHNSON & JOHNSON (2020)
             12.1.6 FUJIFILM HOLDINGS CORPORATION
                        TABLE 134 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 44 COMPANY SNAPSHOT: FUJIFILM HOLDINGS CORPORATION (2020)
             12.1.7 MEDTRONIC, PLC
                        TABLE 135 MEDTRONIC, PLC: BUSINESS OVERVIEW
                        FIGURE 45 COMPANY SNAPSHOT: MEDTRONIC, PLC (2020)
             12.1.8 KARL STORZ SE & CO. KG
                        TABLE 136 KARL STORZ SE & CO. KG.: BUSINESS OVERVIEW
             12.1.9 COOK MEDICAL
                        TABLE 137 COOK MEDICAL: BUSINESS OVERVIEW
             12.1.10 HOYA CORPORATION
                        TABLE 138 HOYA CORPORATION: BUSINESS OVERVIEW
                        FIGURE 46 COMPANY SNAPSHOT: HOYA CORPORATION (2020)
             12.1.11 B. BRAUN MELSUNGEN AG
                        TABLE 139 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
                        FIGURE 47 COMPANY SNAPSHOT: B. BRAUN MELSUNGEN AG (2020)
             12.1.12 HOBBS MEDICAL, INC.
                        TABLE 140 HOBBS MEDICAL, INC.: BUSINESS OVERVIEW
             12.1.13 STERIS PLC
                        FIGURE 48 COMPANY SNAPSHOT: STERIS PLC (2020)
                        TABLE 141 STERIS PLC: BUSINESS OVERVIEW
             12.1.14 MERIT MEDICAL SYSTEMS, INC.
                        TABLE 142 MERIT MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
                        FIGURE 49 COMPANY SNAPSHOT: MERIT MEDICAL SYSTEMS, INC. (2020)
             12.1.15 TELEMED SYSTEMS, INC.
                        TABLE 143 TELEMED SYSTEMS, INC.: BUSINESS OVERVIEW
             12.1.16 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.
                        TABLE 144 CHANGZHOU HEALTH MICROPORT MEDICAL DEVICE CO., LTD.: BUSINESS OVERVIEW
             12.1.17 MEDI-GLOBE GMBH
                        TABLE 145 MEDI-GLOBE GMBH: BUSINESS OVERVIEW
             12.1.18 TAEWOONG MEDICAL CO., LTD.
                        TABLE 146 TAEWOONG MEDICAL CO., LTD.: BUSINESS OVERVIEW
             12.1.19 HUGER MEDICAL INSTRUMENT CO., LTD.
                        TABLE 147 HUGER MEDICAL INSTRUMENT CO., LTD..: BUSINESS OVERVIEW
             12.1.20 INTROMEDIC CO., LTD.
                        TABLE 148 INTROMEDIC CO., LTD.: BUSINESS OVERVIEW
                        FIGURE 50 COMPANY SNAPSHOT: INTROMEDIC CO., LTD. (2020)
             12.1.21 SONOSCAPE MEDICAL CORP.
                        TABLE 149 SONOSCAPE MEDICAL CORP.: BUSINESS OVERVIEW
                        FIGURE 51 COMPANY SNAPSHOT: SONOSCAPE MEDICAL CORP (2020)
     12.2 OTHER PLAYERS
*Details on Business overview, Products offered, Recent developments, MnM view, Right to win, Weakness and competitive threats, and Strategic choices made might not be captured in case of unlisted companies. 

13 APPENDIX (Page No. - 230)
     13.1 DISCUSSION GUIDE
     13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     13.3 AVAILABLE CUSTOMIZATIONS
     13.4 RELATED REPORTS
     13.5 AUTHOR DETAILS

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

The secondary research process involved the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the endoscopic retrograde cholangiopancreatography market. It was also used to obtain important information about the key players and market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations operating in the endoscopic retrograde cholangiopancreatography market. The primary sources from the demand side included industry experts, purchase & sales managers, doctors, and personnel from research organizations. Primary research was conducted to validate the market segmentation, identify key players in the market, and gather insights on key industry trends and key market dynamics.

A breakdown of the primary respondents is provided below:

Endoscopic Retrograde Cholangiopancreatography/ERCP Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the endoscopic retrograde cholangiopancreatography market was arrived at after data triangulation from two different approaches, as mentioned below.

Approach to calculate the revenue of different players in the endoscopic retrograde cholangiopancreatography market

The size of the global endoscopic retrograde cholangiopancreatography market was obtained from annual reports, SEC filings, online publications, and extensive primary interviews. A percentage split was applied to arrive at the size of market segments. Further splits were applied to arrive at the size for each sub-segment. These percentage splits were validated by primary participants. The country-level market sizes obtained from the annual reports, SEC filings, online publications, and extensive primary interviews were added up to reach the total market size for regions. By adding up the market sizes for all the regions, the global endoscopic retrograde cholangiopancreatography market was derived.

Approach to derive the market size and estimate market growth

The market size and market growth were estimated through primary interviews on a regional and global level. All responses were collated, and a weighted average was taken to derive a probabilistic estimate of the market size and growth rate.

Data Triangulation

After arriving at the overall market size-using the market size estimation processes explained above-the market was split into several segments and sub-segments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Objectives of the Study

  • To define, describe, and forecast the endoscopic retrograde cholangiopancreatography market based on product, procedure, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall endoscopic retrograde cholangiopancreatography market
  • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To profile the key players in the market and comprehensively analyze their market shares and core competencies
  • To forecast the size of the market segments with respect to six main regions, namely, North America, Asia Pacific, Europe, Latin America, Middle East, and Africa.
  • To track and analyze competitive developments such as new product launches, agreements, collaborations, and expansions.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific endoscopic retrograde cholangiopancreatography market into South Korea, New Zealand, and other countries
  • Further breakdown of the Rest of Europe endoscopic retrograde cholangiopancreatography market into Belgium, Russia, the Netherlands, Switzerland, and other countries
  • Further breakdown of the Latin America endoscopic retrograde cholangiopancreatography market into the Brazil, Mexico, Argentina, and other countries.
Report Code
MD 8059
Published ON
Mar, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Endoscopic Retrograde Cholangiopancreatography Market/ERCP Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved